Next Article in Journal
Chemical Profile, Cytotoxic Activity and Oxidative Stress Reduction of Different Syringa vulgaris L. Extracts
Previous Article in Journal
Metoprolol and Its Degradation and Transformation Products Using AOPs—Assessment of Aquatic Ecotoxicity Using QSAR
Previous Article in Special Issue
Synthesis and Evaluation of Chalcone Derivatives as Novel Sunscreen Agent
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 11
10.3390/molecules26113103
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies

by
Islam H. El Azab
1,*,
Rania B. Bakr
2 and
Nadia A. A. Elkanzi
3,4
1
Food Science and Nutrition Department, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
2
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
3
Chemistry Department, College of Science, Jouf University, P.O. Box 2014, Sakaka, Saudi Arabia
4
Chemistry Department, Faculty of Science, Aswan University, Aswan, P.O. Box 81528, Aswan, Egypt
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(11), 3103; https://doi.org/10.3390/molecules26113103
Submission received: 15 April 2021 / Revised: 15 May 2021 / Accepted: 19 May 2021 / Published: 22 May 2021
(This article belongs to the Special Issue Application of Organic Synthesis to Bioactive Compounds II)
Browse Figures
Review Reports Versions Notes

Abstract

:
Pyrazolothiazole-substituted pyridine conjugates are an important class of heterocyclic compounds with an extensive variety of potential applications in the medicinal and pharmacological arenas. Therefore, herein, we describe an efficient and facile approach for the synthesis of novel pyrazolo-thiazolo-pyridine conjugate 4, via multicomponent condensation. The latter compound was utilized as a base for the synthesis of two series of 15 novel pyrazolothiazole-based pyridine conjugates (5–16). The newly synthesized compounds were fully characterized using several spectroscopic methods (IR, NMR and MS) and elemental analyses. The anti-proliferative impact of the new synthesized compounds 5–13 and 16 was in vitro appraised towards three human cancer cell lines: human cervix (HeLa), human lung (NCI-H460) and human prostate (PC-3). Our outcomes regarding the anti-proliferative activities disclosed that all the tested compounds exhibited cytotoxic potential towards all the tested cell lines with IC50 = 17.50–61.05 µM, especially the naphthyridine derivative 7, which exhibited the most cytotoxic potential towards the tested cell lines (IC50 = 14.62–17.50 µM) compared with the etoposide (IC50 = 13.34–17.15 µM). Moreover, an in silico docking simulation study was performed on the newly prepared compounds within topoisomerase II (3QX3), to suggest the binding mode of these compounds as anticancer candidates. The in silico docking results indicate that compound 7 was a promising lead anticancer compound which possesses high binding affinity toward topoisomerase II (3QX3) protein.

1. Introduction

The majority of the developed anticancer chemotherapies are not very effective, and side effects might concurrently occur, such as drug-induced impedance. Thus, there is still a critical need to develop novel effective and safe medicines with fewer side effects for the durable treatment of cancer [1,2]. Nitrogen-containing heterocyclic motifs are of high interest owing to their applications as pharmacologically active molecules. These molecules have gained cumulative attention, so they have contributed to the improvement of plentiful organic synthesis protocols and found ample applications in the chemical sciences [3,4,5,6,7]. Several N-heterocyclic conjugates are widely dispersed in nature and are constituents of many biologically important molecules, including several vitamins [8], antibiotics [9], nucleic acids [10], dyes and pharmaceuticals [11,12]. Moreover, the characteristics and utilization of N-heterocyclic skeletons (Figure 1) have gained a reputation in the rapidly growing fields of organic and therapeutic chemistry as well as the pharmaceutical industry [13,14,15]. On the other hand, the electron-donating heterocycle is not only able to readily receive or provide a proton, but it can also simply create various weak connections. Some of the intermolecular connections—for instance, hydrogen-bonding formation, van der Waals forces, dipole–dipole interactions, hydrophobic effects and π-stacking interactions—of N-heterocycles have amplified their significance in the field of therapeutic chemistry and allow them to efficiently adhere to a diversity of enzymes and receptors in drugs due to their improved solubility [16,17,18,19].
Among nitrogen heterocyclic analogues, pyrimidines have numerous applications in medicinal chemistry; the pyrimidine bases of uracil, cytosine and thymine are crucial building blocks of DNA and RNA [20]. In addition, pyrazole-containing scaffolds are a class of heterocycles that exhibit a wide range of biological effects, including anticancer [21], anti-HIV [22], antimalarial [23], anti-tubercular [24], anti-microbial [25] and diabetic activities [26,27].
Hybrid molecules containing thiazole scaffolds are a potential set of heterocyclic compounds; a thiazole core has been found in numerous biologically active natural drugs, such as thiamine (vitamin-B1), penicillin and luciferin [28]. There is a vast number of thiazoles that exhibit a wide range of pharmacological activities, including antibacterial [29], anticancer [30], antifungal [31], anti-inflammatory [32], antioxidant [33] and anti-tubercular activities [34]. Therefore, we believe that the merging of pyrazole and thiazole moieties will result in a class of pharmacophores that exhibit promising biological activities; in fact, several previous works have reported their potential activities, such as anticonvulsant, anti-HIV, anti-inflammatory and anticancer activities [35,36,37,38,39,40].
Based on the aforementioned applications of nitrogen-containing heterocycles, as well as the need for the construction of new bioactive N-heterocycles [41,42,43,44,45,46,47], herein, we report an efficient and facile approach for building up novel nitrogen-containing heterocycles with promising anti-proliferative effects, starting with 2-amino-6-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)nicotinonitrile (4).

2. Results and Discussion

2.1. Chemistry

As an extension of our approach to the intended N-heterocycles [41,42,43,44,45,46,47], we studied the utilization of 2-(1,5-dimethyl-1H-pyrazol-3-yl)-5-acetyl-4-methyl-thiazole (2) to construct a potentially bioactive pyran and/or pyridine hybrids. Thus, coupling of the pyrazolecarbothiamide 1 with 3-chloropentane-2,4-dione in refluxing ethanol afforded the acetyl compound 2 in a 75% yield. Next, a multicomponent reaction of the acetyl compound 2 with thiophene-2-carbaldehyde and malononitrile under reflux in ethanolic piperidine solution yielded the pyran derivative 3. Meanwhile, performing the same reaction with NH4OAc yielded the pyridine analogue 4 in an 81% yield (Scheme 1). A plausible mechanism for the construction of 2-amino-3-cyano pyridine moiety 4 using NH4OAc is displayed in Scheme 2, where the intermediate 2-(thiophen-2-ylmethylene)malononitrile [A], which was obtained via the coupling of thiophene-2-carbaldehyde and malononitrile, was reacted with the thiazoylethenamine [B]; subsequently, an intramolecular cyclization, intermolecular rearrangement and auto oxidation yielded the pyridine analogue 4. The spectral as well as the analytical data of 3 and 4 were consistent with their own structures (see Materials and Methods section).
Then, the reactivity of the o-aminonitrile tag in the pyridine analogue 4 was studied via cyclization with some active methylene compounds, to construct the envisioned pyridine and/or pyrrole nucleus-fused pyridine. Consequently, cyclization of the o-aminonitrile pyridine 4 under basic conditions in EtOH with diethylmalonate and malononitrile afforded 4-amino-1,8-naphthyridines (5 and 6) in fair yields (Scheme 3). Notably, the reaction product of compound 4 with ethyl cyanoacetate was extremely dependent on the reaction conditions. Thus, compound 4 refluxed with ethyl cyanoacetate in ethanolic piperidine solution yielded the 1,8-naphthyridine derivative 7 in a 73% yield, but when the same reaction was carried out under fusion, it yielded 2-cyanomethylpyrido[2,3-d]pyrimidin-4(3H)-one analogue (8) in an 82% yield. A reasonable mechanism for the formation of compound 8 is presented in Scheme 4. This reaction is assumed to proceed via an intermolecular nucleophilic attack of the amino pyridine analogy 4, on the carbonyl carbon in the ethyl canoacetate, leading to the intermediate 4a, and subsequent intramolecular cyclization via further, nucleophilic attack by the -OH moiety on the nitrile group afforded the cyanomethylpyrido[2,3-d][1,3]oxazine derivative 4b. The intermediate 4b undergoing intramolecular Dimroth-like rearrangement afforded the pyrido[2,3-d]pyrimidine analogue 4c, and subsequent elimination of ethanol yielded the pyrido[2,3-d]pyrimidine analogue (8) (Scheme 4).
Moreover, fusing of a pyrrole nucleus with the pyridine moiety in compound 4 was achieved via the condensation of compound 4 with 2-chloroacetonitrile and/or ethyl bromoacetate in refluxing acetone and anhydrous K2CO3, which led to the new pyrrolo[2,3-b]pyridin-3-amine derivatives 9 and 10, respectively (Scheme 3). The IR spectrum of compound 10 disclosed the lack of nitrile absorption that was initially observed in compound 4 (IR), while new absorption bands at 1664 and 3341 cm−1 were assigned to C=O and NH2 groups separately, and its mass spectrum showed an ion peak at m/z 478.12, which confirmed its molecular formula, C23H22N6O2S2. Moreover, the H-resonances of compound 10 showed triplet and quartet signals owing to the ethyl moiety at 1.26 and 4.32 ppm, respectively.
Next, the precursor 4 was subjected to further ring closure by coupling with some amino nucleophiles, which led to a set of pyridopyrimidine analogues (Scheme 5). In consideration of this, we treated compound 4 under reflux with formamide, hydroxylamine hydrochloride, thiourea, 6-methylpyridin-2-amine, 5-amino-3-phenyl-1H-pyrazole and/or 3-amino-1,2,4-triazole to construct pyridopyrimidines (11–16), in fair yields ranging from 65 to 91% (Scheme 5). The absence of nitrile absorbance was clearly observable in the IR spectra of these compounds. The mass spectrum of compound 16 exposed a molecular ion peak at m/z 459.12, which confirmed its molecular formula (C21H17N9S2) (see Supplementary Materials).

2.2. Evaluation of Biological Impact

2.2.1. Cytotoxic Activity

The newly constructed derivatives 5–13 and 16 were evaluated in vitro for their cytotoxic potential towards a prostate cancer cell line (PC-3), lung cancer cell line (NCI-H460) and cervical cancer cell line (Hela) using etoposide as a standard and adapting the MTT assay protocol [48,49]. The obtained outcomes (Table 1, Figure 2) showed that all the tested compounds exhibited cytotoxic potential against PC-3 (IC50 = 17.50–65.41 µM), NCI-H460 (IC50 = 15.42–61.05 µM) and Hela (IC50 = 14.62–59.24 µM) compared to etoposide (IC50 = 17.15, 14.28 and 13.34 µM, respectively). Moreover, 4-Amino-7-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-2-oxo-5-(thiophen-2-yl)-1,2-dihydro-1,8-naphthyridine-3-carbonitrile (7) was the most potent candidate towards PC-3 (IC50 = 17.50 µM), NCI-H460 (IC50 = 15.42 µM) and Hela (IC50 = 14.62 µM), which, in addition, revealed comparable anticancer potential to that exhibited by the standard drug etoposide (IC50 = 17.15, 14.28 and 13.34 µM, respectively). The pyridotriazolopyrimidin-5-amine analogy 16 was the least active candidate (IC50 = 65.41, 61.05 and 59.24 µM, respectively) towards the three tested cell lines, PC-30, NCI-H460 and Hela.
Anticancer activity was calculated using the MTT assay. Results are the average of three independent experiments run in triplicate.

2.2.2. Structure–Activity Relationship

From the data obtained, it is clear that the naphthyridine derivatives 5–7 were the most active compounds against PC-3, NCI-H460 and Hela cell lines (IC50 = 17.5–29.31, 15.42–27.54 and 14.62–25.73, respectively). Within the naphthyridine derivatives, replacing the ethyl carboxylate moiety at C-3 as in compound 5 (IC50 = 25.73–29.31 µM) with the nitrile as in compound 6 (IC50 = 19.31–22.73 µM) and/or compound 7 (IC50 = 14.62–17.50 µM) markedly enhanced the anticancer potential. On the other hand, the presence of an amino group at C-2 of the naphthyridine ring as in compound 6 (IC50 = 19.31–22.73 µM) showed less potency than the 2-oxo moiety in compound 7 (IC50 = 14.62–17.50 µM) against all tested cell lines. Moreover, replacing the naphthyridine ring with the pyrrolo[2,3-b]pyridine system decreased the anticancer activity. This is clear upon comparing compound 7 (IC50 = 14.62–17.50 µM) with the pyrrolopyridine derivative 9 (IC50 = 31.05–35.12 µM). Furthermore, replacing the cyano group at C-2 of the pyrrole ring as in compound 9 (IC50 = 31.05–35.12 µM) with the carboxylate moiety as in compound 10 (IC50 = 45.62–48.29 µM) decreased the cytotoxic potency. Moreover, fusing the pyrimidine derivative 11 (IC50 = 58.12–59.13 µM) with the triazolo ring as in compound 16 (IC50 = 59.24–65.41 µM) reduced the anticancer potential against all tested cell lines.

2.3. Molecular Docking Study

To determine the mechanism of action behind the anticancer activity of the novel constructed compounds, these candidates were docked within topoisomerase II with the use of MOE software, 2010, version 8. An X-ray crystal of topoisomerase II with the cocrystallized ligand etoposide was attained from Protein Data Bank (code: 3QX3). Justification of the docking process was performed by redocking etoposide within topoisomerase II with RMSD = 0.9526. Etoposide formed two hydrogen bonds with AspB479 and DG C13 with binding score = −16.69 kcal/mol (Table 2).
The outcomes from this study illustrate that the novel compounds 5–13 and 16 fitted well within topoisomerase II. The most potent anticancer compound 7 recorded the highest binding energy score (−17.29 kcal/mol), showing two H-bond interactions with AspB479 with the carbonyl and amino groups of the pyridine ring. Moreover, the thiazole moiety of compound 7 recorded arene cation binding with ArgB503 (Figure 3).
On the other hand, compound 6 performed two types of interactions with the topoisomerase II active site. One is hydrophobic binding of the thiophen moiety with DGC13, and the other binding involves hydrogen bond interactions as follows: (i) AspB479 with NH2, and (ii) LysB456 with CN (Figure 4).
Moreover, compound 5 displayed hydrogen-bonding interactions with ArgB503 and DGC13 through binding with NH2 and C=O groups. Moreover, this naphthyridine derivative recorded hydrophobic binding with a thiophen moiety with DAC12 with binding score = −16.16 kcal/mol (Figure 5).
Moreover, the pyrimidine derivative 8 recorded binding energy score = −15.02 kcal/mol, forming three hydrogen bonds as follows (Figure 6):
(i)
DCC11 with carbonyl group;
(ii)
DCC11 with amino group;
(iii)
DGC10 with cyano group.
On the other hand, the cyano group of compound 9 formed a hydrogen bond with ArgB820, with a binding score equal to −17.32 (Figure 7).
The pyrrole moiety of pyrrolopyridine derivative 10 performed arene cation binding with ArgA820 with binding score = −14.06 kcal/mol. In addition, it formed two H-bonds with ArgB503 and DGC13 (Figure 8).
Furthermore, the pyrrole derivative 12 formed two H-bonds with ArgB820 and SerB818 through the nitrogen atom of the pyrrole ring and the amino group with binding score = −14.22 kcal/mol (Figure 9).
Compound 11 recorded a hydrophobic interaction with DAC12 and one hydrogen bond with AlaB816 (Figure 10).
Moreover, the pyridine ring of candidate 13 showed a hydrophobic interaction with DAC12 in addition to forming only one H-bond with DGC13 (Figure 11).
Finally, the least potent cytotoxic agent 16 formed only a hydrophobic interaction between the thiophen ring and DAC12, without displaying any hydrogen bond (Figure 12).

3. Materials and Methods

3.1. General Description of Materials and Methods

The chemicals used in this work were obtained from Sigma Aldrich (Palo Alto, CA, USA) and were used without any further purification.

3.2. Instrumentation

All the synthesized compounds were elucidated by NMR (1H, 13C), MS and IR (see supplementary materials). IR data were documented as KBr discs utilizing a Bruker-Vector 22 FTIR spectrophotometer (Bruker, Manasquan, NJ, USA). The NMR spectra were verified with a Varian Mercury VXR-300 (Bruker, Marietta, GA, USA), at 300 and 75 MHz (1H and 13C-NMR) spectra separately, as a solution in DMSO-d6. The chemical shifts are presented in δ scale relative to the internal reference tetramethylsilane (TMS). Mass spectra were recorded at 70 eV on a Hewlett Packard MS-5988 spectrometer (Hewlett Packard, Palo Alto, CA, USA). Elemental analyses were conducted at the Micro-Analytical Center of Taif University, Taif, Saudi Arabia.

3.3. Synthetic Procedures and Analytic Data of Compounds

1-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)ethanone (2). In an ethanolic solution (40 mL), the pyrazole carbothiamide 1 (0.15 g, 1 mmol) and 3-chloro-2,4-pentanedione (1 mmol) were boiled at reflux for 7 h (tested by TLC). On cooling at ambient temperature, the obtained solid was filtered, washed with cold methanol and recrystallized using EtOH to furnish the acetyl thiazole analogy 2, as a pale yellow solid. Yield: 75%; m.p. 242–244 °C; IR (KBr): (cm−1) 683 (C–S–-C), 1610–1625 (2C=N), 1730 (C=O); 1H-NMR: δ 1.39, 2.02, 3.25 (s, 9H, 3Me), 3.12 (s, 3H, Ac), 6.62 (s, 1H, Pyraz.(C4)-H); 13C-NMR: 10.7, 15.8, 27.4, 38.3 (4Me), 106.8, 138.3, 143.4, 161.2 (2C=C), 136.3, 162.8 (2C=N), 196.5 (C=O); MS (m/z, %): 235.09 (M+, 15); Anal. Calcd. for C11H13N3OS (235.31): C, 56.15; H, 5.57; N, 17.86%. Found: C, 56.01; H, 5.32; N, 17.67%.
2-Amino-6-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)-4H-pyran-3-carbonitrile (3). In a mixture of dry ethanol, piperidine (25 mL:0.5 mL), the acetyl thiazole 2 (0.23 g, 1 mmol), thiophene-2-carbaldehyde (0.12 g, 1 mmol) and malononitrile (0.06 g, 1 mmol) were mixed and refluxed for 3 h (examined by TLC). After cooling the reaction mixture to RT, it was transferred onto ice/H2O and neutralized by HCl, and the solid separated out was isolated, splashed with H2O, dried out and recrystallized by EtOH to yield compound 3 as a buff powder. Yield: 77%; m.p. 172–174 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (2C=N), 2211 (C≡N), 3281 (NH2); 1H-NMR: δ 2.42, 2.45, 3.64 (s, 9H, 3Me), 3.96 (d, 1H, J = 8.5, Pyran.(C4)-H), 5.01 (d, H, J = 8.5, Pyran.(C5)-H), 6.01 (s, 1H, Pyraz.(C4)-H), 6.51 (brs, 2H, NH2 Deutr. Exch), 6.83–7.49 (m, 3H, Thioph.-H); 13C-NMR: 10.7, 15.8, 38.3 (3Me), 29.8 (pyran C-4), 119.1 (C≡N), 58.1, 97.5, 106.3, 123.4, 125.5, 127.0, 138.2, 139.7, 143.0, 153.9, 159.2, 161.0 (6C=C), 136.3, 162.8 (2C=N); MS (m/z, %): 395.09 (M+, 20); Anal. Calcd. for C19H17N5OS2 (395.50): C, 57.70; H, 4.33; N, 17.71%. Found: C, 57.42; H, 4.15; N, 17.51%.
2-Amino-6-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)nicotinonitrile (4). To a solution of the acetyl compound 2 (0.23 g, 1 mmol) in a mixture of dry EtOH (40 mL) containing AcONH4 (0.53 g, 7 mmol), thiophene-2-carbaldehyde (0.12 g, 1 mmol) and malononitrile (0.06 g, 1 mmol) were added and mixed together. The reaction mixture was heated at reflux for 3 h (examined by TLC), then allowed to cool to RT, transferred onto mashed ice and neutralized by HCl, and the solid separated out was collected, splashed with H2O, dried out and recrystallized using EtOH to yield compound 4 as a yellow powder. Yield: 81%; m.p. 158–160 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (2C=N), 2211 (C≡N), 3281 (NH2); 1H-NMR: δ 2.26, 2.40, 2.46 (s, 9H, 3Me), 6.06 (s, 1H, Pyraz.(C4)-H), 6.49 (brs, 2H, NH2 Deutr. Exch), 7.23–7.36 (m, 4H, Thioph.-H and Pyrid.(C5)-H); 13C-NMR: 10.7, 13.8, 38.3 (3Me), 113.7 (C≡N), 86.3, 106.3, 111.7, 126.8, 127.2, 128.2, 128.6, 138.2, 138.5, 148.4, 153.3, 162.2 (6C=C), 136.3, 155.7, 162.8 (3C=N); MS (m/z, %): 392.09 (M+, 40); Anal. Calcd. for C19H16N6S2 (392.50): C, 58.14; H, 4.11; N, 21.41%. Found: C, 58.01; H, 4.02; N, 21.22%.
General method for the synthesis of compounds (5–7). To a solution of pyridine analogy 4 (0.39 g, 1 mmol), in a mixture of ethanol, piperidine (25 mL: 0.3 mL), some selected carbon donors—namely diethylmalonate, malononitrile and ethyl cyanoacetate—were added. Next, the reaction mixture was refluxed for 4–6 h (as tested by TLC), and the solvent was extracted under reduced pressure. The obtained solid was collected, dried and recrystallized by the proper solvent, providing the desired compounds (5–7).
Ethyl 4-amino-7-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-2-oxo-5-(thiophen-2-yl)-1,2-dihydro-1,8-naphthyridine-3-carboxylate (5). After recrystallization using AcOH, compound 5 was attained as yellow crystals. Yield: 79%; m.p. 216–218 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (3C=N), 1648 (amidic C=O), 1729 (ester C=O), 3320–3350 (NH and NH2); 1H-NMR: δ 1.29 (t, 3H, J = 6.5, Me), 2.42, 2.45, 3.64 (s, 9H, 3Me), 3.06 (q, 2H, J = 6.5, CH2), 6.01 (s, 1H, Pyraz.(C4)-H), 6.40 (brs, 2H, NH2 Deutr. Exch), 6.83–7.49 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 10.21 (brs, H, NH Deutr. Exch); 13C-NMR: 10.8, 12.5, 14.2, 38.0 (4Me), 61.0 (CH2), 86.2, 103.1, 106.3, 111.7, 127.6, 127.9, 128.0, 128.6, 138.2, 138.5, 148.6, 152.4, 162.0, 169.6 (7C=C), 136.3, 155.6, 162.8 (3C=N), 161.1, 165.0 (2C=O); MS (m/z, %): 506.12 (M+, 31); Anal. Calcd. for C24H22N6O3S2 (506.60): C, 56.90; H, 4.38; N, 16.59%. Found: C, 56.61; H, 4.12; N, 16.29%.
2,4-Diamino-7-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-5-(thiophen-2-yl)-1,8-naphthyridine-3-carbonitrile (6). After recrystallization using ethanol–DMF (3:1), compound 6 was obtained as a yellow powder. Yield: 71%; m.p. 189–191 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (4C=N), 2210 (C≡N), 3320–3350 (2NH2); 1H-NMR: δ 2.26, 2.40, 2.46 (s, 9H, 3Me), 6.06 (s, 1H, Pyraz.(C4)-H), 5.35, 6.49 (brs, 4H, 2NH2 Deutr. Exch), 7.23–7.36 (m, 4H, Thioph.-H and Pyrid.(C5)-H); 13C-NMR: 10.7, 13.8, 38.3 (3Me), 113.7 (C≡N), 77.8, 86.3, 106.8, 124.3, 126.8, 127.2, 128.2, 128.6, 138.2, 138.5, 148.4, 155.3, 158.3, 162.0 (7C=C), 136.3, 155.7, 162.2, 162.8 (4C=N); MS (m/z, %): 458.04 (M+, 47); Anal. Calcd. for C22H18N8S2 (458.56): C, 57.62; H, 3.96; N, 24.44%. Found: C, 57.41; H, 3.68; N, 24.30%.
4-Amino-7-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-2-oxo-5-(thiophen-2-yl)-1,2-dihydro-1,8-naphthyridine-3-carbonitrile (7). After recrystallization using DMF–MeOH (1:3), compound 7 was obtained as brownish-yellow fine grains. Yield: 73%; m.p. 159–161 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (3C=N), 2210 (C≡N), 3280 (NH2); 1H-NMR: δ 2.42, 2.45, 3.64 (s, 9H, 3Me), 5.62 (brs, 2H, NH2 Deutr. Exch), 6.01 (s, 1H, Pyraz.(C4)-H), 6.83–7.49 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 10.12 (brs, 1H, NH Deutr. Exch); 13C-NMR: 10.8, 12.5, 38.0 (3Me), 115.8 (C≡N), 80.7, 106.3, 111.1, 112.3, 127.6, 128.0, 128.6, 138.2, 138.4, 144.2, 149.8, 176.8 (6C=C), 136.3, 151.3, 162.8 (3C=N), 168.3 (C=O); MS (m/z, %): 459.10 (M+, 10); Anal. Calcd. for C22H17N7OS2 (459.55): C, 57.50; H, 3.73; N, 21.34%. Found: C, 57.29; H, 3.41; N, 21.15%.
2-(7-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-oxo-5-(thiophen-2-yl)-3,4-dihydropyrido [2,3-d]pyrimidin-2-yl)acetonitrile (8). Without any solvent, the pyridine analogy 4 (0.39 g, 1 mmol) and ethyl cyanoacetate (10 mL) were fused for 5 h. After cooling to RT, the reaction mixture was triturated with cold ethanol, and the separated solid was extracted and recrystallized by EtOH, to provide the cyanomethyl pyrimidine analogy 8, in an 82% yield; m.p. 253–256 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (4C=N), 1645 (C=O amide), 2210 (C≡N), 3280 (NH); 1H-NMR: δ 2.42, 2.45, 3.64 (s, 9H, 3Me), 4.12 (s, 2H, CH2), 6.01 (s, 1H, Pyraz.(C4)-H), 6.83–7.49 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 10.12 (brs, 1H, NH Deutr. Exch); 13C-NMR: 10.8, 12.5, 38.0 (3Me), 22.4 (CH2), 116.3 (C≡N), 106.3, 118.5, 121.5, 127.6, 127.9, 128.0, 128.6, 138.2, 138.4, 147.5, 152.4, 154.0 (6C=C), 136.3, 152.1, 156.4, 162.8 (4C=N), 161.0 (C=O); MS (m/z, %): 459.09 (M+, 41); Anal. Calcd. for C22H17N7OS2 (459.55): C, 57.50; H, 3.73; N, 21.34%. Found: C, 57.29; H, 3.41; N, 21.15%.
General Procedure for the Synthesis of Compounds (9 and 10). To a solution of compound 4 (0.39 g, 1 mmol) and anhydrous K2CO3 (1.37 g) in dry acetone (25 mL), chloroacetonitrile and/or ethyl bromoacetate (20 mmol) was added. After, the reaction mixture was refluxed for 5 h (monitored by TLC), and the extra solvent was removed under reduced pressure. The resulted rough matter was triturated by cold MeOH, and the separated solid was filtered, washed, dried and recrystallized to give compounds 9 and 10.
3-Amino-6-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile (9). After recrystallization using methanol compound 9 obtained as an off-white solid. Yield: 78%; m.p. 261–263 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1612–1625 (3C=N), 2208 (C≡N), 3320–3350 (NH and NH2); 1H-NMR: 2.26, 2.40, 2.46 (s, 9H, 3Me), 6.06 (s, 1H, Pyraz.(C4)-H), 6.61 (brs, 2H, NH2 Deutr. Exch), 7.23 -7.36 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 9.61 (brs, 1H, NH Deutr. Exch); 13C-NMR: 10.7, 13.8, 38.3 (3Me), 113.7 (C≡N), 101.8, 106.8, 118.6, 124.3, 126.8, 127.2, 128.2, 128.6, 138.2, 138.6, 148.4, 153.3, 158.3, 162.9 (7C=C), 136.3, 155.7, 162.2, 162.8 (4C=N); MS (m/z, %): 431.11 (M+, 41); Anal. Calcd. for C21H17N7S2 (431.54): C, 58.45; H, 3.97; N, 22.72%. Found: C, 58.21; H, 3.69; N, 22.42%.
Ethyl 3-amino-6-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (10). After recrystallization using dioxane, compound 11 was obtained as a pale yellow solid. Yield: 73%; m.p. 275–257 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1612–1625 (3C=N), 1664 (C=O), 3320–3341 (NH and NH2); 1H-NMR: δ 1.29 (t, 3H, J = 6.5, Me), 2.42, 2.45, 3.64 (s, 9H, 3Me), 4.32 (q, 2H, J = 6.5, CH2), 6.01 (s, 1H, Pyraz.(C4)-H), 6.32 (brs, 2H, NH2 Deutr. Exch), 6.83–7.49 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 10.62 (brs, 1H, NH Deutr. Exch); 13C-NMR: 10.8, 12.5, 14.1, 38.0 (4Me), 60.9 (CH2), 106.3, 108.3, 118.5, 121.5, 130.2, 127.6, 127.9, 128.0, 128.6, 138.2, 138.4, 147.5, 152.4, 154.0 (7C=C), 136.3, 151.1, 162.8 (C=N), 161.0 (C=O); MS (m/z, %): 478.12 (M+, 32); Anal. Calcd. for C23H22N6O2S2 (478.59): C, 57.72; H, 4.63; N, 17.56%. Found: C, 57.43; H, 4.51; N, 17.33%.
7-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-4-amine (11). The pyridine analogue 4 (0.39 g, 1 mmol) and formamide (10 mL) were fused face to face for 3 h. Afterwards, the separated brown solid on cooling was collected and dried. A brown solid with an 80% yield was obtained after recrystallization using EtOH; m.p. over 300 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (5C=N), 3385 (NH2); 1H-NMR: δ 2.42, 2.45, 3.64 (s, 9H, 3Me), 6.01 (s, 1H, Pyraz.(C4)-H), 6.32 (brs, 2H, NH2 Deutr. Exch), 6.83–7.49 (m, 5H, Thioph.-H, Pyrid.(C5)-H and Pyrimi.(C2)-H); 13C-NMR: 10.8, 12.5, 38.0 (3Me), 105.2, 106.3, 121.5, 127.7, 127.9, 128.0, 128.6, 138.2, 141.9, 144.9, 152.4, 157.8 (6C=C), 136.3, 151.2, 152.3, 157.4, 162.8 (5C=N); MS (m/z, %): 419.10 (M+, 9); Anal. Calcd. for C20H17N7S2 (419.53): C, 57.26; H, 4.08; N, 23.37%. Found: C, 57.11; H, 4.02; N, 23.17%.
6-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)-1H-pyrazolo[3,4-b] pyridin-3-amine (12). Compound 4 (0.39 g, 1 mmol) was refluxed for 3h with NH2OH.HCl (0.07 g, 0.1 mmol) in AcOH acid (25 mL) having anhydrous AcONa (0.08 g, 0.1 mmol) as a catalyst. Afterwards, the reaction mixture was decanted onto cold H2O, and the formed precipitate was filtered, dried and recrystallized from EtOH, affording a reddish-brown powder in a 91% yield; m.p. 286–288 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (4C=N), 3320–3355 (NH and NH2); 1H-NMR: δ 2.42, 2.45, 3.64 (s, 9H, 3Me), 6.01 (s, 1H, Pyraz.(C4)-H), 6.41 (brs, 2H, NH2 Deutr. Exch), 6.83–7.49 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 12.61 (brs, H, NH Deutr. Exch); MS (m/z, %): 407.10 (M+, 53); Anal. Calcd. for C19H17N7S2 (407.52): C, 56.00; H, 4.20; N, 24.06%. Found: C, 55.82; H, 4.11; N, 23.79%.
General Method for the Synthesis of Compounds (13–16). To a solution of the pyridine derivative 4 (0.39 g, 1 mmol), in AcOH acid (25 mL), equimolar amounts of some amino nucleophiles—namely urea, 6-methylpyridin-2-amine, 3-phenyl-1H-pyrazol-5-amine, and/or 1,2,4-triazin-3-amine—were added. Afterwards, the reaction mixture was refluxed for 6–8 h (Monitored by TLC analysis). After the solvent was evaporated in vacuo, the rough product was mushed with cold MeOH. The formed solid was isolated and then recrystallized to obtain compounds (13–16).
4-Amino-7-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidine-2(1H)-thione (13). This was obtained as an orange-yellow solid after recrystallization using ethanol in a 72% yield; m.p. 197–199 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1345 (thioamidic C=S), 1612–1625 (4C=N), 3210–3348 (NH, NH2); 1H-NMR: 2.26, 2.40, 2.46 (s, 9H, 3Me), 6.06 (s, 1H, Pyraz.(C4)-H), 6.61 (brs, 2H, NH2 Deutr. Exch), 7.23–7.59 (m, 4H, Thioph.-H and Pyrid.(C5)-H), 10.27 (brs, 1H, NH Deutr. Exch); 13C-NMR: 10.7, 13.8, 38.3 (3Me), 106.8, 118.6, 124.3, 127.2, 128.2, 128.6, 138.2, 138.6, 148.4, 153.3, 158.3, 162.9 (6C=C), 136.3, 155.7, 162.2, 162.8 (4C=N), 180.4 (C=S); MS (m/z, %): 451.07 (M+, 23); Anal. Calcd. for C20H17N7Ss (451.59): C, 53.19; H, 3.79; N, 21.71%. Found: C, 53.10; H, 3.51; N, 21.48%.
2-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-10-methyl-4-(thiophen-2-yl)-5H-dipyrido[1,2-a:3′,2′-e]pyrimidin-5-imine (14). This was obtained as a yellow powder after recrystallization using dioxane in a 65% yield; m.p. 263–265 °C; IR (KBr): (cm−1) 675–6810 (2C–S–C), 1612–1625 (5C=N), 3219 (NH); 1H-NMR: δ 2.26, 2.42, 2.45, 3.64 (s, 12H, 4Me), 6.01 (s, 1H, Pyraz.(C4)-H), 6.83–7.49 (m, 7H, Thioph.-H and Pyrid.(C3-5)-H), 8.92 (brs, H, N=H Deutr. Exch); MS (m/z, %): 483.13 (M+, 41); Anal. Calcd. for C25H21N7Ss (483.61): C, 62.09; H, 4.38; N, 20.27%. Found: C, 61.79; H, 4.11; N, 20.10%.
8-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-2-phenyl-6-(thiophen-2-yl)pyrazolo [1,5-a]pyrido[3,2-e]pyrimidin-5-amine (15). This was obtained as a yellow solid after recrystallization using MeOH/dioxane (3:1) in an 80% yield; m.p. 215–217 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (5C=N), 3385 (NH2); 1H-NMR: δ 2.42, 2.45, 3.64 (s, 9H, 3Me), 6.01 (s, 1H, Pyraz.(C4)-H), 6.52 (brs, 2H, NH2 Deutr. Exch), 6.83–7.49 (m, 11H, Ar-H, Thioph.-H, Pyrid.(C5)-H and Pyrimi.(C2)-H); 13C-NMR: 10.8, 12.5, 38.0 (3Me), 92.5, 105.2, 106.3, 121.7, 127.5, 127.6, 127.9, 128.0, 128.6, 128.7, 129.2, 133.0, 138.2, 141.9, 144.9, 149.4, 152.4, 159.2 (10C=C), 136.3, 152.3, 155.6, 157.4, 162.8 (5C=N); MS (m/z, %): 534.14 (M+, 17); Anal. Calcd. for C28H22N8S2 (534.66): C, 62.90; H, 4.15; N, 20.96%. Found: C, 62.71; H, 4.02; N, 20.69%.
2-(2-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5-amine (16). This was obtained as faint yellow crystals after recrystallization using EtOH in a 75% yield; m.p. 218–220 °C; IR (KBr): (cm−1) 675–681 (2C–S–C), 1610–1625 (6C=N), 3385 (NH2); 2.26, 2.40, 2.46 (s, 9H, 3Me), 6.06 (s, 1H, Pyraz.(C4)-H), 6.61 (brs, 2H, NH2 Deutr. Exch), 7.27–7.59 (m, 5H, Thioph.-H, Pyrid.(C5)-H and Triaz.(C3)-H); 13C-NMR: 10.7, 13.8, 38.3 (3Me), 106.8, 118.6, 124.3, 127.2, 128.2, 128.6, 138.2, 138.6, 148.4, 153.3, 158.3, 162.9 (6C=C), 136.0, 136.3, 155.3, 157.0, 162.2, 162.8 (6C=N); MS (m/z, %): 459.12 (M+, 55); Anal. Calcd. for C21H17N9S2 (459.55): C, 54.89; H, 3.73; N, 27.43%. Found: C, 54.59; H, 3.41; N, 27.22%.

3.4. Assessment of Anticancer Activity

MTT Cytotoxicity Assay

The in vitro growth inhibitory activity of the ten achieved analogues was explored in comparison with a notable anti-malignancy standard medication, etoposide, adapting the colorimetric MTT assay in triplicate as described previously [48]. In brief, cells were seeded onto 96-well tissue culture plates in DMEM containing 10% FBS to a final volume of 0.2 mL. The cells were subjected to different treatments after 24 h of seeding. The cells were then incubated for 48 h with etoposide (positive controls), test drugs or vehicle (DMSO). The media were then removed, replaced with 200 lL DMEM containing 0.5 mg/mL of MTT and cells were incubated for 2 h. Next, the supernatants were removed and the precipitated formazan was dissolved by adding 200 lL of DMSO. Absorbance at 570 nm was determined using a microplate reader (Model 450 Microplate Reader; Bio-Rad). Results were calculated by subtracting blank readings.

3.5. Docking Study

Topoisomerase II crystal structure with the cocrystallized ligand (etoposide) was downloaded from Protein Data Bank (PDB code: 3QX3). The target derivatives 5–13 and 16 were docked within the topoisomerase II active site using the MOE 2010 program. To validate the docking step, etoposide was redocked with RMSD = 0.9526. Three-dimensional structures of the target derivatives were built, protonated and energy minimized and saved as mdb files to be docked within topoisomerase II. The results of the docking study are given in Table 2.

3.6. Statistical Analysis

The presented results are mean ± SD, and the statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. Differences were considered significant at p < 0.05. Statistical analysis was performed using SPSS for Windows (SPSS, Inc., Chicago, IL, USA).

4. Conclusions

In this work, we described an efficient and facile approach for the synthesis of 2-amino-6-(2-(1,5-dimethyl-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-4-(thiophen-2-yl)nicotinonitrile (4), via one-pot multicomponent condensation, as a reactive precursor to synthesize novel pyrazolothiazole-based pyridine conjugates (5–16). All the target derivatives 5–13 and 16 were evaluated for their cytotoxic activity towards prostate cancer (PC-3), lung cancer (NCI-H460) and cervical cancer (Hela) cell lines. All the tested compounds revealed anticancer activity towards PC-3 (IC50 = 17.50–65.41 µM), NCI-H460 (IC50 = 15.42–61.05 µM) and Hela (IC50 = 14.62–59.24 µM). Analysis of the structure–activity relationship (SAR) indicated that the naphthyridine hybrids had more favorable cytotoxic potential than pyridopyrimidine, pyrrolopyridine and/or pyrido[3,2-e][1,2,4]triazolo[4,3-a] pyrimidine hybrids. A docking study was performed within the topoisomerase II active site to predict the binding mechanism of these compounds. All the docked compounds demonstrated good fitting within topoisomerase II. The most potent cytotoxic compound 7 (IC50 = 14.62–17.50 µM) displayed the best docking score (−17.29 Kcal/mol), forming two hydrogen bonds with the AspB479 amino acid, while the least potent cytotoxic compound 16 (59.24–65.41 µM) did not show any hydrogen bond with the enzyme and bound with DAC12 via hydrophobic binding with the lowest binding score (−10.98 Kcal/mol).

Supplementary Materials

The following are available online. MS, 1H NMR, 13C NMR of compounds 2, 4, 6, 9, 13, 16.

Author Contributions

Conceptualization: I.H.E.A.; preparation and characterization of the heterocyclic compounds: I.H.E.A. and N.A.A.E.; writing—original draft, design of the experiments, formal analysis and discussion of the results: I.H.E.A., N.A.A.E. and R.B.B.; contributions to the antitumor study and completing of the docking study: R.B.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Taif University grant number TURSP-2020/27.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in this article.

Acknowledgments

This work was supported by Taif University researchers supporting project number (TURSP-2020/27), Taif University, Taif, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are not available from authors.

References

  1. Wang, T.T.; Liu, J.; Zhong, H.Y.; Chen, H.; Lv, Z.L.; Zhang, Y.K.; Zhang, M.F.; Geng, D.P.; Niu, C.J.; Li, Y.M.; et al. Synthesis and anti-tumor activity of novel ethyl 3-aryl-4-oxo-3,3a,4,6-tetrahydro-1H-furo[3,4-c]pyran-3a-carboxylates. Bioorg. Med. Chem. Lett. 2011, 21, 3381. [Google Scholar] [CrossRef] [PubMed]
  2. Sangthong, S.; Krusong, K.; Ngamrojanavanich, N.; Vilaivan, T.; Puthong, S.; Chandchawan, S.; Muangsin, N. Synthesis of rotenoid derivatives with cytotoxic and topoisomerase II inhibitory activities. Bioorg. Med. Chem. Lett. 2011, 21, 4813. [Google Scholar] [CrossRef]
  3. Li, X.; He, L.; Chen, H.; Wu, W.; Jiang, H. Copper-catalyzed aerobic C(sp2)–H functionalization for C–N bond formation: Synthesis of pyrazoles and indazoles. J. Org. Chem. 2013, 78, 3636–3646. [Google Scholar] [CrossRef] [PubMed]
  4. Santos, C.M.M.; Freitas, M.; Fernandes, E. A comprehensive review on xanthone derivatives as α-glucosidase inhibitors. Eur. J. Med. Chem. 2018, 157, 1460–1479. [Google Scholar] [CrossRef] [PubMed]
  5. Kalaria, P.N.; Karad, S.C.; Raval, D.K. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. Eur. J. Med. Chem. 2018, 158, 917–936. [Google Scholar] [CrossRef] [PubMed]
  6. Kerru, N.; Bhaskaruni, S.V.H.S.; Gummidi, L.; Maddila, S.N.; Maddila, S.; Jonnalagadda, S.B. Recent advances in heterogeneous catalysts for the synthesis of imidazole derivatives. Synth. Commun. 2019, 49, 2437–2459. [Google Scholar] [CrossRef]
  7. Kerru, N.; Singh, P.; Koorbanally, N.; Raj, R.; Kumar, V. Recent advances (2015–2016) in anticancer hybrids. Eur. J. Med. Chem. 2017, 142, 179–212. [Google Scholar] [CrossRef]
  8. Ma, Y.Z.; Tang, Z.B.; Sang, C.Y.; Qi, Z.Y.; Hui, L.; Chen, S.W. Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 2019, 29, 694–699. [Google Scholar] [CrossRef]
  9. Kerru, N.; Maddila, S.; Jonnalagadda, S.B. Design of carbon–carbon and carbon–heteroatom bond formation reactions under green conditions. Curr. Org. Chem. 2019, 23, 3156–3192. [Google Scholar] [CrossRef]
  10. Xu, Z.; Zhao, S.J.; Liu, Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur. J. Med. Chem. 2019, 183, 111700. [Google Scholar] [CrossRef]
  11. Zarate, D.Z.; Aguilar, R.; Hernandez-Benitez, R.I.; Labarrios, E.M.; Delgado, F.; Tamariz, J. Synthesis of α-ketols by functionalization of captodative alkenes and divergent preparation of heterocycles and natural products. Tetrahedron 2015, 71, 6961–6978. [Google Scholar] [CrossRef]
  12. Abdellatif, K.R.A.; Fadaly, W.A.; Kamel, G.M.; Elshaier, Y.A.; El-Magd, M.A. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. Bioorg. Chem. 2019, 82, 86–99. [Google Scholar] [CrossRef]
  13. Fang, W.Y.; Ravindar, L.; Rakesh, K.P.; Manukumar, H.M.; Shantharam, C.S.; Alharbi, N.S.; Qin, H.L. Synthetic approaches and pharmaceutical applications of chloro-containing molecules for drug discovery: A critical review. Eur. J. Med. Chem. 2019, 173, 117–153. [Google Scholar] [CrossRef]
  14. Kerru, N.; Singh-Pillay, A.; Awolade, P.; Singh, P. Current anti-diabetic agents and their molecular targets: A review. Eur. J. Med. Chem. 2018, 152, 436–488. [Google Scholar] [CrossRef]
  15. Takate, S.J.; Shinde, A.D.; Karale, B.K.; Akolkar, H.; Nawale, L.; Sarkar, D.; Mhaske, P.C. Thiazolyl-pyrazole derivatives as potential antimycobacterial agents. Bioorg. Med. Chem. Lett. 2019, 29, 1199–1202. [Google Scholar] [CrossRef]
  16. Nagaraju, K.; Lalitha, G.; Suresh, M.; Kranthi, K.G.; Sreekantha, B.J. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. Molecules 2020, 25, 1909. [Google Scholar] [CrossRef]
  17. Shu, L.; Chen, C.; Huan, X.; Huang, H.; Wang, M.; Zhang, J.; Yan, Y.; Liu, J.; Zhang, T.; Zhang, D. Design, synthesis, and pharmacological evaluation of 4- or 6-phenylpyrimidine derivatives as novel and selective Janus kinase 3 inhibitors. Eur. J. Med. Chem. 2020, 191, 112148. [Google Scholar] [CrossRef]
  18. Wang, R.; Yu, S.; Zhao, X.; Chen, Y.; Yang, B.; Wu, T.; Hao, C.; Zhao, D.; Cheng, M. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Eur. J. Med. Chem. 2020, 188, 112024. [Google Scholar] [CrossRef]
  19. Diao, P.C.; Lin, W.Y.; Jian, X.E.; Li, Y.H.; You, W.W.; Zhao, P.L. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity. Eur. J. Med. Chem. 2019, 179, 196–207. [Google Scholar] [CrossRef]
  20. Kaur, R.; Chaudhary, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review. Eur. J. Med. Chem. 2017, 132, 108–134. [Google Scholar] [CrossRef]
  21. Chaudhari, K.; Surana, S.; Jain, P.; Patel, H.M. Mycobacterium tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB. Eur. J. Med. Chem. 2016, 124, 160–185. [Google Scholar] [CrossRef] [PubMed]
  22. Sameem, B.; Saeedi, M.; Mahdavi, M.; Shafiee, A. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease. Eur. J. Med. Chem. 2017, 128, 332–345. [Google Scholar] [CrossRef] [PubMed]
  23. Akhtar, J.; Khan, A.A.; Ali, Z.; Haider, R.; Yar, M.S. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. Eur. J. Med. Chem. 2017, 125, 143–189. [Google Scholar] [CrossRef] [PubMed]
  24. Ma, X.; Lv, X.; Zhang, J. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. Eur. J. Med. Chem. 2018, 143, 449–463. [Google Scholar] [CrossRef] [PubMed]
  25. Kaur, R.; Dahiya, L.; Kumar, M. Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus. Eur. J. Med. Chem. 2017, 141, 473–505. [Google Scholar] [CrossRef] [PubMed]
  26. Modi, P.; Patel, S.; Chhabria, M. Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents. Bioorg. Chem. 2019, 87, 240–251. [Google Scholar] [CrossRef] [PubMed]
  27. Yang, F.; Yu, L.Z.; Diao, P.C.; Jian, X.E.; Zhou, M.F.; Jiang, C.S.; You, W.W.; Wei-Feng, M.; Zhao, P.L. Novel[1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities. Bioorg. Chem. 2019, 92, 103260. [Google Scholar] [CrossRef] [PubMed]
  28. Hananya, N.; Shabat, D. A Glowing Trajectory between Bio- and Chemiluminescence: From LuciferinBased Probes to Triggerable Dioxetanes. Angew. Chem. Int. Ed. 2017, 56, 16454–16463. [Google Scholar] [CrossRef]
  29. Chen, K.; Yao, X.; Tang, T.; Chen, L.-M.; Xiao, C.; Wang, J.-Y.; Chen, H.-F.; Jiang, Z.-X.; Liu, Y.; Zheng, X. Thiazole-based and thiazolidine-based protein tyrosine phosphatase 1B inhibitors as potential antidiabetes agents. Med. Chem. Res. 2020, 1–16. [Google Scholar] [CrossRef]
  30. Sayed, A.R.; Gomha, S.M.; Taher, E.A.; Muhammad, Z.A.; El-Seedi, H.R.; Gaber, H.M.; Ahmed, M.M. One-Pot Synthesis of Novel Thiazoles as Potential Anticancer Agents. Drug Des. Dev. Ther. 2020, 14, 1363–1375. [Google Scholar] [CrossRef] [Green Version]
  31. Lino, C.I.; Gonçalves de Souza, I.; Borelli, B.M.; Silvério Matos, T.T.; Santos Teixeira, I.N.; Ramos, J.P.; Maria de Souza Fagundes, E.; de Oliveira Fernandes, P.; Maltarollo, V.G.; Johann, S.; et al. Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives. Eur. J. Med. Chem. 2018, 151, 248–260. [Google Scholar] [CrossRef]
  32. Maghraby, M.T.E.; Abou-Ghadir, O.M.F.; Abdel-Moty, S.G.; Ali, A.Y.; Salem, O.I.A. Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes. Bioorg. Med. Chem. 2020, 28. [Google Scholar] [CrossRef]
  33. Dhameliya, T.M.; Tiwari, R.; Banerjee, A.; Pancholia, S.; Sriram, D.; Panda, D.; Chakraborti, A.K. Benzo[d]thiazole-2-carbanilides as new anti-TB chemotypes: Design, synthesis, biological evaluation, and structure-activity relationship. Eur. J. Med. Chem. 2018, 155, 364–380. [Google Scholar] [CrossRef]
  34. Grozav, A.; Porumb, I.-D.; Găină, L.I.; Filip, L.; Hanganu, D. Cytotoxicity and Antioxidant Potential of Novel 2-(2-((1H-indol-5yl)methylene)-hydrazinyl)-thiazole Derivatives. Molecules 2017, 22, 260. [Google Scholar] [CrossRef] [Green Version]
  35. Guerrero-Pepinosa, N.Y.; Cardona-Trujillo, M.C.; Garzon-Castano, S.C.; Veloza, L.A.; Sepúlveda-Arias, J.C. Antiproliferative activity of thiazole and oxazole derivatives: A systematic review of in vitro and in vivo studies. Biomed. Pharmacother. 2021, 138, 111495. [Google Scholar] [CrossRef]
  36. Luzina, E.L.; Popov, A.V. Synthesis and anticancer activity of N-bis(trifluoromethyl)alkyl-N’-thiazolyl and N-bis(trifluoromethyl)alkyl-N’- benzothiazolyl ureas. Eur. J. Med. Chem. 2009, 44, 4944–4953. [Google Scholar] [CrossRef]
  37. Satoh, A.; Nagatomi, Y.; Hirata, Y.; Ito, S.; Suzuki, G.; Kimura, T.; Maehara, S.; Hikichi, H.; Satow, A.; Hata, M.; et al. Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol- 2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorg. Med. Chem. Lett. 2009, 19, 5464–5468. [Google Scholar] [CrossRef]
  38. Havrylyuk, D.; Zimenkovsky, B.; Vasylenko, O.; Zaprutko, L.; Gzella, A.; Lesyk, R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur. J. Med. Chem. 2009, 44, 1396–1404. [Google Scholar] [CrossRef]
  39. George, R.F.; Samir, E.M.; Abdelhamed, M.N.; Abdel-Aziz, H.A.; Abbas, S.E.-S. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. Bioorg. Chem. 2019, 83, 186–197. [Google Scholar] [CrossRef]
  40. Kaminskyy, D.; Zimenkovsky, B.; Lesyk, R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. Eur. J. Med. Chem. 2009, 44, 3627–3636. [Google Scholar] [CrossRef]
  41. El Azab, I.H.; Elkanzi, N.A.A. Design, Synthesis, and Antimicrobial Evaluation of New Annelated Pyrimido[2,1-c][1,2,4]triazolo[3,4-f][1,2,4]triazines. Molecules 2020, 25, 1339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. El Azab, I.H.; Elkanzi, N.A.A. An Efficient Synthetic Approach Towards Benzo[b]pyrano[2,3-e][1,4]diazepines and Their Cytotoxic Activity. Molecules 2020, 25, 2051. [Google Scholar] [CrossRef] [PubMed]
  43. El Azab, I.H.; Elkanzi, N.A.A.; Gobouri, A.A. Design and Synthesis of Some New Quinoxaline-Based Heterocycles. J. Heterocycl. Chem. 2018, 55, 65–76. [Google Scholar] [CrossRef]
  44. El Azab, I.H.; Gobouri, A.A.; Altalhi, T.A. 4-Chlorothiazole-5-carbaldehydes as Potent Precursors for Synthesis of Some New Pendant N-heterocyces Endowed with Anti-Tumor Activity. J. Heterocycl. Chem. 2019, 56, 281–295. [Google Scholar] [CrossRef] [Green Version]
  45. El Azab, I.H.; Elkanzi, N.A.A.; Gobouri, A.A.; Altalhi, T.A. Convenient Synthesis of Novel Nitrogen Bridgehead Heterocycles Utilizing 3-Mercapto-6H-[1,2,4,5]oxatriazino[3,2-a]isoindol-6-one as a New Synthon. J. Heterocycl. Chem. 2019, 56, 60–72. [Google Scholar] [CrossRef] [Green Version]
  46. El Azab, I.H.; Abu Ali, O.A.; El-Zahrani, A.H.; Gobouri, A.A.; Altalhi, T.A. Pyrazole-1-carbothioamide as a Potent Precursor for Synthesis of Some New N-heterocycles of Potential Biological Activity. J. Heterocycl. Chem. 2019, 56, 18–31. [Google Scholar] [CrossRef] [Green Version]
  47. El Azab, I.H.; Khalifa, M.E.; Gobouri, A.A.; Altalhi, T.A. Synthesis, Characterization, and Pharmacological Evaluation of Some New Pteridine-Based Heterocycles as Antimicrobial Agents. J. Heterocycl. Chem. 2019, 56, 1352–1361. [Google Scholar] [CrossRef]
  48. Mohamed, A.A.; Rania, B.B.; Olla, A.A.; Wafaa, R.M. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors. Bioorg. Chem. 2016, 66, 88–96. [Google Scholar] [CrossRef]
  49. Omar, H.A.; Arafa, E.-S.A.; Salama, S.A.; Arab, H.H.; Wu, C.-H.; Weng, J.-R. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt–NF-κB and MAPK signaling pathways. Toxicol. Appl. Pharmacol. 2013, 272, 616–624. [Google Scholar] [CrossRef]
Molecules 26 03103 g001 550
Figure 1. Representative examples of bioactive nitrogen-containing compounds.
Figure 1. Representative examples of bioactive nitrogen-containing compounds.
Molecules 26 03103 g001
Molecules 26 03103 sch001 550
Scheme 1. Synthesis of pyran and pyridine analogues 3 and 4.
Scheme 1. Synthesis of pyran and pyridine analogues 3 and 4.
Molecules 26 03103 sch001
Molecules 26 03103 sch002 550
Scheme 2. The plausible mechanism for the formation of 2-amino-3-cyano pyridine core 4.
Scheme 2. The plausible mechanism for the formation of 2-amino-3-cyano pyridine core 4.
Molecules 26 03103 sch002
Molecules 26 03103 sch003 550
Scheme 3. Synthesis of compounds 5–10.
Scheme 3. Synthesis of compounds 5–10.
Molecules 26 03103 sch003
Molecules 26 03103 sch004 550
Scheme 4. The reasonable mechanism for the formation of cyanomethylpyrido[2,3-d]pyrimidine derivative (8).
Scheme 4. The reasonable mechanism for the formation of cyanomethylpyrido[2,3-d]pyrimidine derivative (8).
Molecules 26 03103 sch004
Molecules 26 03103 sch005 550
Scheme 5. Synthesis of compounds 11–16.
Scheme 5. Synthesis of compounds 11–16.
Molecules 26 03103 sch005
Molecules 26 03103 g002 550
Figure 2. In vitro cytotoxic results of the target compounds 5–13, 16 and etoposide towards PC-3, NCI-H460 and Hela cell lines.
Figure 2. In vitro cytotoxic results of the target compounds 5–13, 16 and etoposide towards PC-3, NCI-H460 and Hela cell lines.
Molecules 26 03103 g002
Molecules 26 03103 g003 550
Figure 3. The suggested binding mode of compound 7 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 3. The suggested binding mode of compound 7 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g003
Molecules 26 03103 g004 550
Figure 4. The suggested binding mode of compound 6 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 4. The suggested binding mode of compound 6 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g004
Molecules 26 03103 g005 550
Figure 5. The suggested binding mode of compound 5 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within Topoisomerase II.
Figure 5. The suggested binding mode of compound 5 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within Topoisomerase II.
Molecules 26 03103 g005
Molecules 26 03103 g006 550
Figure 6. The suggested binding mode of compound 8 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 6. The suggested binding mode of compound 8 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g006
Molecules 26 03103 g007 550
Figure 7. The suggested binding mode of compound 9 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 7. The suggested binding mode of compound 9 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g007
Molecules 26 03103 g008 550
Figure 8. The suggested binding mode of compound 10 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 8. The suggested binding mode of compound 10 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g008
Molecules 26 03103 g009 550
Figure 9. The suggested binding mode of compound 12 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 9. The suggested binding mode of compound 12 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g009
Molecules 26 03103 g010 550
Figure 10. The suggested binding mode of compound 11 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 10. The suggested binding mode of compound 11 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g010
Molecules 26 03103 g011 550
Figure 11. The suggested binding mode of compound 13 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 11. The suggested binding mode of compound 13 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g011
Molecules 26 03103 g012 550
Figure 12. The suggested binding mode of compound 16 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Figure 12. The suggested binding mode of compound 16 within topoisomerase II. (A) 3D binding mode within the active site. (B) 2D binding mode within topoisomerase II.
Molecules 26 03103 g012
Table
Table 1. In vitro cytotoxic results of the target compounds 5–13, 16 and etoposide towards PC-3, NCI-H460 and Hela cell lines.
Table 1. In vitro cytotoxic results of the target compounds 5–13, 16 and etoposide towards PC-3, NCI-H460 and Hela cell lines.
Compound No.In Vitro Cytotoxicity IC50 (μM) ± SD
PC-3NCI-H460Hela
529.31 ± 0.9127.54 ± 0.4325.73 ± 1.62
622.73 ± 1.4021.12 ± 1.3119.31 ± 0.45
717.50 ± 0.3515.42 ± 0.3214.62 ± 0.52
828.62 ± 1.1526.92 ± 0.3226.31 ± 0.46
935.12 ± 0.2632.81 ± 0.5131.05 ± 0.87
1048.29 ± 0.3647.12 ± 1.0845.62 ± 1.34
1159.13 ± 1.1258.64 ± 1.4158.12 ± 0.41
1249.08 ± 0.9248.13 ± 0.5247.13 ± 0.95
1356.71 ± 0.8755.03 ± 0.6153.76 ± 1.67
1665.41 ± 0.7561.05 ± 0.7559.24 ± 1.20
Etoposide17.15 ± 0.2414.28 ± 0.1513.34 ± 0.23
Table
Table 2. Docking outcomes for compounds 5–13, 16 and etoposide within topoisomerase II (code: 3QX3).
Table 2. Docking outcomes for compounds 5–13, 16 and etoposide within topoisomerase II (code: 3QX3).
Target No.E. Score Kcal/molNumber of Hydrogen BondsDistance (A°) from Amino AcidBound Group
5−16.1621.88
1.75		DGC13
ArgB503		C=O
NH2
6−16.7922.11
2.37		AspB479
LysB456		NH2
CN
7−17.2922.29
2.05		AspB479
AspB479		C=O
OH
8−15.0233.25
2.96
3.01		DCC11
DCC11
DGC10		C=O
NH
CN
9−17.3213.06ArgB820CN
10−14.0622.84
3.09		ArgB503
DGC13		NH2
C=O
11−12.5813.07AlaB816NH2
12−14.2221.98
2.27		ArgB820
SerB818		Pyrrole N
NH2
13−12.8712.56DGC13Pyrimidine NH
16−10.980---
Etoposide−16.6921.89
1.87		AspB479
DGC13		OH
OH
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

El Azab, I.H.; Bakr, R.B.; Elkanzi, N.A.A. Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies. Molecules 2021, 26, 3103. https://doi.org/10.3390/molecules26113103

AMA Style

El Azab IH, Bakr RB, Elkanzi NAA. Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies. Molecules. 2021; 26(11):3103. https://doi.org/10.3390/molecules26113103

Chicago/Turabian Style

El Azab, Islam H., Rania B. Bakr, and Nadia A. A. Elkanzi. 2021. "Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies" Molecules 26, no. 11: 3103. https://doi.org/10.3390/molecules26113103

APA Style

El Azab, I. H., Bakr, R. B., & Elkanzi, N. A. A. (2021). Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies. Molecules, 26(11), 3103. https://doi.org/10.3390/molecules26113103

Article Metrics

Back to TopTop